2011 and before

Posters

  • O. H.-U. SCHROEDER, K. JÜGELT, B. M. BADER, A. GRAMOWSKI-VOSS. Comparison of classical and allosteric GABAB modulators by their electrophysiological activity patterns on in vitro microcircuits from frontal cortex tissue. Program No. 233.06. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online.

  • B. M. BADER, C. FAHRUN, M. ZWAR, K. JÜGELT, O. H.-U. SCHROEDER, A. GRAMOWSKI. A novel developmental in vitro assay: Functional characterization and quantification of GABAA receptor subunits during cortical development. Program No. 41.08. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online.

  • B. M. BADER, S. KNIEST, K. JÜGELT, M. KRIEBEL, H. VOLKMER, O. H.-U. SCHROEDER, A. GRAMOWSKI-VOSS. Enhanced predictive drug development: Functional screening of the GABAAR α1 subunit using receptor-specific RNA inference, MEA recordings and substance classification. Program No. 41.13. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online.

  • K. JÜGELT, O. H.-U. SCHROEDER, A. GRAMOWSKI-VOSS. Highly sensitive tetrodotoxin assay: Cortical network activity responses 500-fold more sensitive than associated action potential waveform changes. Program No. 760.17. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online.

  • L. SCHULTZ, B. M. BADER, K. JÜGELT, A. GRAMOWSKI-VOSS, O. H.-U. SCHROEDER. Profiling the complex mode of action of clozapine as a lead compound in antipsychotics drug development - Functional screening with primary neuronal networks on MEA neurochips. Program No. 567.22. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online.

Talks

  • IDDST 2010 - Beijing/China: Dr. Olaf Schröder, CEO, NeuroProof: "Screening of Compounds Acting on GPCRs with MEA-Neurochip technology"